MediVet America, the catalyst of the MediVet brand as the world’s leader in Veterinary regenerative medicine will announce on Jan 6, 2015 a change in name to MediVet Biologics. The new brand includes a new logo, company mission and customer materials. A new website will also launch today, improving users online experience. The rebranding reflects the many recent changes the company has undergone globally uniting the Veterinary holdings of Medical Australia which include MediVet America, TutaVet & MediVet Pty Ltd. The rebranding will also serve to better define the products and services offered by MediVet for the large and small animal market as well as its vision for the future.
MediVet serves an international progressive network of thousands of veterinarians with products such as Platelet Rich Plasma, Adipose Derived Stem Cell Treatments, and Autologous Conditioned Serum (IRAP ACS). The company has several Research and Development projects in the pipeline including other breakthrough biologic therapies coming to market in 2015.
In an effort to continue the advancement of the animal regenerative medicine space and provide the most, efficacious, and widely used provider of these therapies, MediVet Biologics continues to invest in the research and validation of the science. As of January 6th, 2015 the company has several ongoing R&D studies/projects at, The University of Kentucky, College of Medicine, University of Georgia College of Veterinary Medicine, & Kansas State University.
“Our in-clinic adipose derived stem cell treatments have been very well received by the North American Veterinary market and have allowed us to assist animals as well as add brick and mortar value to Veterinarian practices in a shifting and dynamic market. We look forward to expanding our brand domestically in the US as well as globally,” Jeremy Delk, C.E.O. MediVet Biologics.